Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Susumu Kobayashi, M.D.

TitleAssistant Professor of Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Med Ctr
E/cls 0407
330 Brookline Ave
Boston MA 02215
Phone617/735-2229
Fax617/735-2222

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2013 Jan; 8(1):45-51.
    View in: PubMed
  2. Ackerman A, Goldstein MA, Kobayashi S, Costa DB. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):e19-20.
    View in: PubMed
  3. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012 Jul; 7(7):1086-90.
    View in: PubMed
  4. Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, Sukhatme VP. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol. 2012 Apr; 227(4):1709-20.
    View in: PubMed
  5. Costa DB, Kobayashi S. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. J Thorac Oncol. 2012 Mar; 7(3):623-5.
    View in: PubMed
  6. Basseres DS, D'Alò F, Yeap BY, Löwenberg EC, Gonzalez DA, Yasuda H, Dayaram T, Kocher ON, Godleski JJ, Richards WG, Meyerson M, Kobayashi S, Tenen DG, Halmos B, Costa DB. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7.
    View in: PubMed
  7. Kawahara H, Watanabe K, Ushigome T, Noaki R, Kobayashi S, Yanaga K. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer. Hepatogastroenterology. 2012 Jan-Feb; 59(113):134-7.
    View in: PubMed
  8. Kawahara H, Watanabe K, Ushigome T, Yanagisawa S, Kobayashi S, Yanaga K. Lateral pelvic lymph node dissection using latero-vesical approach with aspiration procedure for advanced lower rectal cancer. Hepatogastroenterology. 2012 Jan-Feb; 59(113):116-9.
    View in: PubMed
  9. Yano M, Sasaki H, Moriyama S, Hikosaka Y, Yokota K, Kobayashi S, Hara M, Fujii Y. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg. 2012 Feb; 14(2):146-50.
    View in: PubMed
  10. Nguyen KS, Sanford RA, Huberman MS, Goldstein MA, McDonald DM, Farquhar M, Gangadharan SP, Kent MS, Michaud G, Majid A, Berman SM, Aronovitz JA, Nedea EA, Boiselle PM, Cohen DW, Kobayashi S, Costa DB. Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. J Oncol Pract. 2012 Jan; 8(1):57-62.
    View in: PubMed
  11. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012 Jan; 13(1):e23-31.
    View in: PubMed
  12. Akiba T, Marushima H, Kamiya N, Odaka M, Kinoshita S, Takeyama H, Kobayashi S, Morikawa T. Thoracoscopic lobectomy for treating cancer in a patient with an unusual vein anomaly. Ann Thorac Cardiovasc Surg. 2011; 17(5):501-3.
    View in: PubMed
  13. Akiba T, Tabei I, Kinoshita S, Yanagisawa S, Kobayashi S, Odaka M, Takeyama H, Morikawa T. Three-dimensional computed tomography for lung cancer in a patient with three right vein ostia. Gen Thorac Cardiovasc Surg. 2011 May; 59(5):376-9.
    View in: PubMed
  14. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner KD. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011 May 20; 29(15):e443-5.
    View in: PubMed
  15. Usuba T, Misawa T, Toyama Y, Ishida Y, Ishii Y, Yanagisawa S, Kobayashi S, Yanaga K. Is modified Devine exclusion necessary for gastrojejunostomy in patients with unresectable pancreatobiliary cancer? Surg Today. 2011 Jan; 41(1):97-100.
    View in: PubMed
  16. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010 Nov; 1(7):497-514.
    View in: PubMed
  17. Costa DB, Kobayashi S, Yeo WL, Hamada A. Serum concentrations of Erlotinib at a dose of 25 mg daily. J Thorac Oncol. 2010 Aug; 5(8):1311-2.
    View in: PubMed
  18. Akiba T, Marushima H, Kawahara H, Takagi M, Hirano J, Odaka M, Nakanishi K, Takeyama H, Kobayashi S, Morikawa T. Video-assisted thoracic surgery for patients with lung cancer and interstitial pneumonia. Ann Thorac Cardiovasc Surg. 2010 Aug; 16(4):236-41.
    View in: PubMed
  19. Kawahara H, Watanabe K, Ushigome T, Noaki R, Kobayashi S, Yanaga K. Where is the best skin incision for partial resection of the small intestine? Hepatogastroenterology. 2010 Jul-Aug; 57(101):794-6.
    View in: PubMed
  20. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53.
    View in: PubMed
  21. O'Brien KB, Alberich-Jordà M, Yadav N, Kocher O, Diruscio A, Ebralidze A, Levantini E, Sng NJ, Bhasin M, Caron T, Kim D, Steidl U, Huang G, Halmos B, Rodig SJ, Bedford MT, Tenen DG, Kobayashi S. CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development. 2010 Jul; 137(13):2147-56.
    View in: PubMed
  22. Will B, Siddiqi T, Jordà MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010 Apr 8; 115(14):2901-9.
    View in: PubMed
  23. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, Halmos B. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis. 2010 Apr; 31(4):577-86.
    View in: PubMed
  24. Akiba T, Marushima H, Harada J, Kobayashi S, Morikawa T. Importance of preoperative imaging with 64-row three-dimensional multidetector computed tomography for safer video-assisted thoracic surgery in lung cancer. Surg Today. 2009; 39(10):844-7.
    View in: PubMed
  25. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53.
    View in: PubMed
  26. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009 Jul; 10(4):281-9.
    View in: PubMed
  27. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009 May 15; 15(10):3484-94.
    View in: PubMed
  28. Costa DB, Kobayashi S. Gefitinib plus docetaxel in non-small-cell lung cancer. Lancet. 2009 Feb 14; 373(9663):541; author reply 542.
    View in: PubMed
  29. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 1; 14(21):7060-7.
    View in: PubMed
  30. Akiba T, Marushima H, Harada J, Kobayashi S, Morikawa T. Anomalous pulmonary vein detected using three-dimensional computed tomography in a patient with lung cancer undergoing thoracoscopic lobectomy. Gen Thorac Cardiovasc Surg. 2008 Aug; 56(8):413-6.
    View in: PubMed
  31. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul 15; 68(14):5827-38.
    View in: PubMed
  32. Cha HC, Oak NR, Kang S, Tran TA, Kobayashi S, Chiang SH, Tenen DG, MacDougald OA. Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes. J Biol Chem. 2008 Jun 27; 283(26):18002-11.
    View in: PubMed
  33. Saitoh T, Kuramochi K, Imai T, Takata K, Takehara M, Kobayashi S, Sakaguchi K, Sugawara F. Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro. Bioorg Med Chem. 2008 May 15; 16(10):5815-25.
    View in: PubMed
  34. Hayashi T, Kawahara H, Kobayashi S, Kashiwagi H, Hirai K, Yanaga K. Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors. Hepatogastroenterology. 2008 Mar-Apr; 55(82-83):403-6.
    View in: PubMed
  35. Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 2008 Mar 1; 26(7):1182-4; author reply 1184-6.
    View in: PubMed
  36. Costa DB, Kobayashi S. Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations. J Clin Oncol. 2008 Feb 1; 26(4):686.
    View in: PubMed
  37. Costa DB, Kobayashi S, Schumer ST. Erlotinib-associated alopecia in a lung cancer patient. J Thorac Oncol. 2007 Dec; 2(12):1136-8.
    View in: PubMed
  38. Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007 Nov 1; 67(21):10417-27.
    View in: PubMed
  39. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680.
    View in: PubMed
  40. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007 Sep; 117(9):2611-20.
    View in: PubMed
  41. Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Müller-Tidow C, Serve H, Tenen DG. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007 Nov 15; 110(10):3695-705.
    View in: PubMed
  42. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103.
    View in: PubMed
  43. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 1; 66(23):11389-98.
    View in: PubMed
  44. Uchiyama A, Mukai M, Fujiwara Y, Kobayashi S, Kawai N, Murofushi H, Inoue M, Enoki S, Tanaka Y, Niki T, Kobayashi T, Tigyi G, Murakami-Murofushi K. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochim Biophys Acta. 2007 Jan; 1771(1):103-12.
    View in: PubMed
  45. Kubo S, Levantini E, Kobayashi S, Kocher O, Halmos B, Tenen DG, Takahashi M. Three-dimensional magnetic resonance microscopy of pulmonary solitary tumors in transgenic mice. Magn Reson Med. 2006 Sep; 56(3):698-703.
    View in: PubMed
  46. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95.
    View in: PubMed
  47. Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS, Kutok JL, Gilliland DG, Krauter J, Tenen DG. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6338-43.
    View in: PubMed
  48. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005 Aug 17; 97(16):1185-94.
    View in: PubMed
  49. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15; 65(16):7096-101.
    View in: PubMed
  50. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92.
    View in: PubMed
  51. Ito Y, Kobayashi S, Taniguchi T, Kainuma O, Hara T, Ochiai T. Frequent detection of K-ras mutation in stool samples of colorectal carcinoma patients after improved DNA extraction: comparison with tissue samples. Int J Oncol. 2002 Jun; 20(6):1263-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Kobayashi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (286) concept(s)
_
Co-Authors
See all (59) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_